
-
Vericel NasdaqGM:VCEL Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Location: 64 Sidney Street, Cambridge, MA, 02139, United States | Website: https://www.vcel.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
2.068B
Cash
112.9M
Avg Qtr Burn
N/A
Short % of Float
8.48%
Insider Ownership
1.06%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
MACI® (Matrix-Induced Autologous Chondrocyte Implantation) Details Symptomatic chondral or osteochondral defects of the knee | Approved Quarterly sales | |
NexoBrid® (anacaulase-bcdb) Details Thermal burns | Approved Quarterly sales | |
MACI® (Matrix-Induced Autologous Chondrocyte Implantation) Details Cartilage defects/injuries, Cartilage damage in the ankle | Phase 3 Initiation |